The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2022 |
Davide Ciardiello, Brigida Anna Maiorano, Paola Parente, Maria Grazia Rodriquenz, Tiziana Pia Latiano, Cinzia Chiarazzo, Valerio Pazienza, Luigi Pio Guerrera, Brunella Amoruso, Nicola Normanno, Giulia Martini, Fortunato Ciardiello, Erika Martinelli, Evaristo Maiello. Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives, International Journal of Molecular Sciences. 2022; 23: 820. https://doi.org/10.3390/ijms23020820 |
|
2 |
2023 |
Amit Mahipal, Mathias Palmer, Jennifer Gile, Richard Kim. Durvalumab: A PD-L1 Blocking Antibody for the Treatment of Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer, Oncology & Haematology. 2023; 19: 22. https://doi.org/10.17925/OHR.2023.19.1.22 |
|
3 |
2023 |
Senmiao Huang, Dianhe Li, Yongye Huang, Guojie Lu, Ying Tian, Xuefeng Zhong, Yating Zheng, Mengli Huang, Fuxi Huang. An unresectable and metastatic intrahepatic cholangiocarcinoma with EML4-ALK rearrangement achieving partial response after first-line treatment with ensartinib: a case report, Frontiers in Oncology. 2023; 13: 1191646. https://doi.org/10.3389/fonc.2023.1191646 |
|
4 |
2024 |
Santiago Sucre, Andrea Bullock, Mary Linton Peters. Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma, BMJ Case Reports. 2024; 17: e255003. https://doi.org/10.1136/bcr-2023-255003 |